# BCL-XL inhibitor payloads

Source: https://onco.cc/terms/bcl-xl-inhibitor-payloads/  
OnCo record `bcl-xl-inhibitor-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

These payloads release a brake that can stop damaged cells from dying. Attaching the drug to an antibody aims to concentrate that effect in cancer cells.

## Summary

BCL-XL is an anti-apoptotic protein. Primary preclinical research tested BCL-XL inhibitor conjugates and showed that drug-linker changes altered cardiovascular, kidney and platelet toxicities in animal studies. The resulting linker-payload was incorporated into the B7-H3-directed mirzotamab clezutoclax, or ABBV-155. The original solid-tumor trial is completed in the registry. This represents an apoptosis-directed payload, not proof that antibody targeting removes all toxicity from BCL-XL inhibition.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: clezutoclax; mirzotamab clezutoclax; ABBV-155

## Sources

- Judd et al., BCL-XL inhibitor conjugates (2024): https://doi.org/10.1126/sciadv.ado7120
- ClinicalTrials.gov: NCT03595059: https://clinicaltrials.gov/study/NCT03595059

## Connected records

- terms: [MCL-1 inhibitor payloads](https://onco.cc/terms/mcl1-inhibitor-payloads/), [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)

---
JSON: https://onco.cc/api/v1/entities/bcl-xl-inhibitor-payloads.json